Nucleic Acid Based Assay Involving A Hybridization Step With A Nucleic Acid Probe, Involving A Single Nucleotide Polymorphism (snp), Involving Pharmacogenetics, Involving Genotyping, Involving Haplotyping, Or Involving Detection Of Dna Methylation Gene Expression Patents (Class 435/6.11)
  • Patent number: 10316063
    Abstract: A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: June 11, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Steffen Walter, Jens Fritsche, Colette Song, Harpreet Singh
  • Patent number: 10308979
    Abstract: This disclosure provides a method comprising: a) clamping the top and bottom strands of a double stranded DNA molecule to produce a duplex in which the top and bottom strands are linked; b) denaturing the duplex to produce a denatured product; and c) renaturing the denatured product in the presence of a labeled oligonucleotide that is complementary to a sequence of nucleotides in the double stranded DNA molecule, thereby producing a D-loop-containing product. Kits for performing the method and products made by the method are also provided.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 4, 2019
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Brian Jon Peter, Robert A. Ach, Zoltan Timar, Joel Myerson, Jeffrey Robert Sampson, Holly Hogrefe
  • Patent number: 10301679
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: May 28, 2019
    Assignee: Celera Corporation
    Inventors: Steven J. Schrodi, Ann Begovich
  • Patent number: 10301619
    Abstract: Compositions and methods are provided for forming a single RNA polynucleotide from a plurality of DNA oligonucleotides in a single reaction chamber using combined reagents in a single step reaction. DNA polymerase, RNA polymerase and single stranded (ss) DNA oligonucleotides are combined where each DNA oligonucleotide has one or more sequence modules, wherein one sequence module in the first ss DNA oligonucleotide is complementary to a sequence module at the 3? end of the second ss DNA oligonucleotide; and wherein a second module on the first ss DNA oligonucleotide is an RNA polymerase promoter sequence; and forming a single RNA polynucleotide, excluding the RNA promoter sequence, derived from the first and second DNA oligonucleotides.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: May 28, 2019
    Assignee: New England Biolabs, Inc.
    Inventors: G. B. Robb, Isaac B. Meek, Dianne S. Schwarz, Ezra Schildkraut
  • Patent number: 10301686
    Abstract: The present invention relates to a method for specifically detecting Mycobacterium tuberculosis and nontuberculous mycobacteria by simultaneously amplifying and analyzing target genes using various primers and probes, and a kit using same. The method of the present invention is capable of selectively detecting Mycobacterium tuberculosis and nontuberculous mycobacteria with very high efficiency through a multiplex real-time polymerase chain reaction (PCR) using probes and primers specific to target genes (particularly, IS6110, 16S rRNA and ?-actin). Also, the kit of the present invention is capable of conveniently and efficiently detecting the target genes in a sample through a multiplex real-time PCR. Therefore, the method and the kit of the present invention are capable of selectively detecting with ease whether or not there is an infection with Mycobacterium tuberculosis or nontuberculous mycobacteria in a sample, and can be more accurately applied to the treatment of diseases on the basis thereof.
    Type: Grant
    Filed: March 19, 2014
    Date of Patent: May 28, 2019
    Assignee: HYUNIL-BIO CO.
    Inventor: Jeong Uk Kim
  • Patent number: 10301675
    Abstract: In one aspect, compositions and methods for reducing reverse transcriptase (RT) inhibition in RT-PCR are provided. In some embodiments, the RT inhibition reducer is a phosphorothioate oligodeoxycytosine (SdC), phosphorothioate oligodeoxyadenine (SdA), phosphorothioate oligodeoxythymine (SdT), or phosphorothioate oligodeoxyguanosine (SdG).
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 28, 2019
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Xiao-Song Gong, Yan Wang
  • Patent number: 10302614
    Abstract: Food distributed to consumers through a distribution chain may be traced by tagging the food with DNA tags that identify the origin of the food, such as the grower, packer and other points of distribution, and their attributes. This makes it much quicker and easier to trace the food in case of food contamination or adulteration. Preferably these attributes indicate the field, location, crew and machine used to grow and process the food, and the dates of the various steps of food harvesting, processing and distribution. Natural or synthetic DNA pieces may be used to tag items, including food items. Multidigit binary or other types of bar codes may be represented by multiple types of DNA. Each digit of the bar code may be represented by one, two or more unique DNA pieces.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: May 28, 2019
    Assignees: SafeTraces, Inc., Lawrence Livermore National Security, LLC
    Inventors: Antonios Zografos, George Roy Farquar
  • Patent number: 10302591
    Abstract: Pre-labeled protein standards useful in electrophoresis that have sharp, consistent separation characteristics that are substantially the same as those of their unlabeled counterparts are provided. The invention provides pre-labeled protein standard sets that include a plurality of labeled proteins that are labeled on a first amino acid, in which side reactions of the label with amino acids not targeted for labeling are reduced.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: May 28, 2019
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Roumen Bogoev, Douglas Kang
  • Patent number: 10294519
    Abstract: A convenient method for nucleic acid analysis is provided, which enables 1000 or more types of nucleic acid to be analyzed collectively with high comprehensiveness and with a dynamic range of at least four digits. In particular, provided is a very effective analytical method especially for untranslated RNAs and microRNAs, of which the types of target nucleic acids is 10000 or lower. Nucleic acids can be analyzed conveniently and rapidly with high comprehensiveness and quantitative performance at single-molecule sensitivity and resolution by following the steps of: preparing a group of target nucleic acid fragments one molecule at a time and hybridizing the nucleic acid molecules, which have known base sequences and have been labeled with the fluorescence substances, with the group of the target nucleic acid fragments to detect the fluorescence substances labeling the hybridized nucleic acid molecules.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: May 21, 2019
    Assignee: Hitachi High-Technologies Corporation
    Inventors: Toshiro Saito, Koshin Hamasaki, Satoshi Takahashi, Muneo Maeshima, Kyoko Imai, Kazumichi Imai, Ryuji Tao
  • Patent number: 10294525
    Abstract: To introduce a biomolecule into a nanopore without the need to check the position of the nanopore in a thin film. In addition, displacement stability is ensured and stable acquisition of blocking signals is realized. An immobilization member 107 having a larger size than a thin film 113 with a nanopore 112 is used, and biomolecules are immobilized on the biomolecule immobilization member 107 at a density that allows at least one biomolecule 108 to enter an electric field region around the nanopore when the biomolecule immobilization member 107 has moved close to a nanopore device 101.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: May 21, 2019
    Assignee: Hitachi High-Technologies Corporation
    Inventors: Rena Akahori, Itaru Yanagi, Kenichi Takeda
  • Patent number: 10294529
    Abstract: The present application relates to the field of cancer, particularly to mismatch repair (MMR?) deficient tumors. New markers are presented herein that have a high sensitivity to detect whether a tumor is mismatch repair deficient or not. The markers are particularly mutations in microsatellite regions. Accordingly, methods are provided for diagnosing microsatellite instability of a tumor, comprising determining the presence of these markers. Further, kits are provided to detect the presence of these markers (or subsets thereof) in a sample.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: May 21, 2019
    Assignees: Life Sciences Research Partners VZW, VIB VZW
    Inventor: Diether Lambrechts
  • Patent number: 10294534
    Abstract: The present invention provides nucleic acid products and corresponding methods for screening a biological sample for the presence of a respiratory infection-causing microorganism.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: May 21, 2019
    Assignee: THE SECRETARY OF STATE FOR HEALTH
    Inventor: Martin Curran
  • Patent number: 10288608
    Abstract: The present disclosure provides polynucleotide conjugates, methods, and assay systems for use in detecting the presence, absence, and/or amount of an analyte in a sample. Various polynucleotide conjugates, conjugate pairs, sets, libraries, and assay systems comprising the same are disclosed. In particular, methods and assay systems for antibody detection and analysis are provided. For example, assays capable of high levels of multiplexing are used for antibody detection and analysis in a biological sample, e.g., Lyme disease patient samples. The presently disclosed polynucleotide conjugates, methods, and assay systems can be used to provide sensitive and reliable diagnosis, even at early stages of a disease or condition. Use for monitoring disease progression and prognosis is also disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: May 14, 2019
    Assignee: Prognosys Biosciences, Inc.
    Inventors: Igor A. Kozlov, John Andrew Altin, Petr Capek, Mark S. Chee
  • Patent number: 10287582
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: May 14, 2019
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
  • Patent number: 10290387
    Abstract: Methods for precise and predictable modification of previously synthesized nanocrystals. The methods rely on the solubility behavior of crystalline materials to provide for controlled reversal of the nanocrystal growth process (i.e., dissolution). A method for post-synthesis modification of colloidal nanocrystals includes (1) providing a first nanocrystal having a first size and a first shape, (2) forming a reaction mixture that includes the nanocrystal, at least one ligand capable of binding to at least one component of the nanocrystal, at least one solvent, and an inert gas atmosphere, and (3) modifying the size and/or shape of the nanocrystal in the reaction mixture for a period of time at a temperature in a range from about 100° C. to about 240° C. so as to produce at least a second nanocrystal having a second size and/or a second shape.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: May 14, 2019
    Assignee: University of Utah Research Foundation
    Inventors: Michael Hans Risbud Bartl, Jacqueline T. Siy
  • Patent number: 10287620
    Abstract: Methods of determining polymerase fidelity are provided. In one embodiment, the method comprises filling a gapped plasmid with a polymerase to form a gap-filled plasmid, wherein the gap-filled plasmid comprises a gene encoding an protein that is functional or non-functional depending on the polymerase fidelity; forming a plurality of partitions from a solution comprising the gap-filled plasmid and a label for detecting the presence of the plasmid; detecting the presence of the gap-filled plasmid in one or more of the partitions; and determining the fidelity of the polymerase by determining a ratio of partitions containing the gene encoding a functional protein to partitions containing a gene encoding a non-functional protein.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 14, 2019
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Man Cheng, Xiangdong Meng, Jan Zur Megede
  • Patent number: 10287584
    Abstract: In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell. In certain embodiments, the target nucleic acid is a nucleic acid that encodes cartilage oligomeric matrix protein. In certain embodiments, the target nucleic acid is a nucleic acid expressed in the growth plate, tendon, or cartilage.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: May 14, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Shuling Guo, Punit P. Seth, Jacqueline T. Hecht, Karen LaShea Posey
  • Patent number: 10279332
    Abstract: A substrate comprising a coating of a masking material, and a plurality of discrete reaction zones onto which one or more binding agents are intended to be attached, wherein said zones are uncoated areas on the substrate.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: May 7, 2019
    Assignees: RANDOX LABORATORIES LTD., RANDOX TEORANTA
    Inventors: Peter Fitzgerald, John Lamont, Ivan McConnell, Elouard Benchikh, Deepesh Upadhyay, Ciaran Richardson
  • Patent number: 10280392
    Abstract: Methods and devices for non-thermal PCR amplification of nucleic acid sequences. An electrical potential is applied to cause non-thermal separation of strands of a double-stranded nucleic acid or double-stranded nucleic acid/primer extension product.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: May 7, 2019
    Assignee: The Regents of the University of California
    Inventor: Hemantha Kumar Wickramasinghe
  • Patent number: 10272137
    Abstract: The present disclosure describes the fusogenic activity of the Myomaker protein. This polypeptide, when expressed in non-muscle cells, is able to drive fusion of the cell with a muscle cell, but not with other non-muscle cells. The use of this protein and cell expressing it in the delivery of exogenous genetic material to muscle cells also is described.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 30, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Eric Olson, Douglas P. Millay
  • Patent number: 10273537
    Abstract: Real time redox sequencing methods, devices, and systems are described. Arrays of redox devices comprising one or two electrodes are used to provide sequence information about a template nucleic acid in a polymerase-template complex bound proximate to the electrode(s). A sequencing reaction mixture comprising nucleotide analogs comprising redox labels is introduced to the array of redox devices under conditions of polymerase mediated nucleic acid synthesis. The time sequence of incorporation of nucleotide analogs is determined by electrochemically identifying the redox labels of the nucleotide analogs that are incorporated into the growing strand.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: April 30, 2019
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Jonas Korlach, Stephen Turner, Lei Sun
  • Patent number: 10273529
    Abstract: Methods and assays are provided for isolating factors including polypeptides, ribonucleic acids (RNAs) and polypeptide complexes that are associated with a target nucleic acid sequence. The target nucleic acid sequence may be comprised within chromatin. The methods are suitable for identification and characterisation of factors including non-coding RNAs (ncRNAs) that associate with specified genomic loci.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: April 30, 2019
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Robert Kingston, Matthew Simon, Jason Allen West
  • Patent number: 10272076
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: April 30, 2019
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Curt D. Wolfgang, Mihael H. Polymeropoulos
  • Patent number: 10266889
    Abstract: The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: April 23, 2019
    Assignees: ROCHE FINANCE LTD, INTEGRATED DNA TECHNOLOGIES, INC.
    Inventors: Mark Aaron Behlke, John Robert Havens, Mirna Jarosz, Zachary Zwirko, Doron Lipson, Frank Soo Juhn
  • Patent number: 10267769
    Abstract: A method for fixing a biological sample includes delivering energy through a biological sample that has been removed from a subject, while fixing the biological sample. A change in speed of the energy traveling through the biological sample is evaluated to monitor the progress of the fixation. A system for performing the method can include a transmitter that outputs the energy and a receiver configured to detect the transmitted energy. A computing device can evaluate the speed of the energy based on signals from the receiver.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: April 23, 2019
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Michael Otter, David Chafin, Abbey Pierson, Jefferson Curtis Taft
  • Patent number: 10268964
    Abstract: A method is disclosed for determining a minimum connected dominating set in a graph, the method comprising obtaining an indication of an input graph, the input graph comprising a plurality of nodes and a plurality of edges; generating a distance table comprising for each node of the input graph, an indication of a distance between the given node and each of the other node of the plurality of nodes; generating a corresponding constrained binary quadratic programming problem using the generated distance table; providing the corresponding constrained binary quadratic programming problem to a quantum annealing solver; obtaining at least one approximate solution from the quantum annealing solver; post-processing the at least one approximate solution and providing the post-processed at least one approximate solution.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 23, 2019
    Assignee: 1QB INFORMATION TECHNOLOGIES INC.
    Inventors: Seyed Saeed Changiz Rezaei, Brad Woods, Pooya Ronagh
  • Patent number: 10260100
    Abstract: The present invention relates to neuropathy, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: April 16, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, BAYLOR COLLEGE OF MEDICINE
    Inventors: Miriam Meisler, James R. Lupski, Clement Chow
  • Patent number: 10262104
    Abstract: Presented herein are methods and compositions for determining haplotypes in a sample. The methods are useful for obtaining sequence information regarding, for example, HLA type and haplotype. Also presented herein are methods of determining haplotypes in a sample based on a plurality sequence reads.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 16, 2019
    Assignee: ILLUMINA, INC.
    Inventors: Thomas Royce, Craig April, Fiona Kaper, Jian-Bing Fan
  • Patent number: 10260070
    Abstract: Provided are an aptamer having an inhibitory activity against NGF; a complex containing an aptamer having a binding activity or inhibitory activity against NGF and a functional substance (e.g., affinity substances, labeling substances, enzymes, drug delivery vehicles, drugs and the like); a medicament, a diagnostic agent, a labeling agent and the like containing an aptamer having a binding activity or inhibitory activity against NGF, or a complex containing the aptamer and the functional substance; and the like.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: April 16, 2019
    Assignees: RIBOMIC INC., FUJIMOTO PHARMACEUTICAL CORPORATION
    Inventors: Ling Jin, Shin Miyakawa, Masatoshi Fujiwara, Yoshikazu Nakamura, Hisanao Hiramatsu
  • Patent number: 10254281
    Abstract: FHL1 (Four-and-a-half-LIM domain 1) is identified as a new muscle specific autoantigen. Detection of autoantibodies for FHL1 in a sample obtained from a human subject are useful for diagnosis of autoimmune muscle diseases, including myositis, polymyositis, dermatomyositis, inclusion body myositis, and immune mediated necrotizing myopathy. FHL1 and FHL1 derived peptides are used for the treatment of autoimmune muscle diseases.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 9, 2019
    Assignee: STIFTELSEN VECTIS
    Inventors: Inka Albrecht, Ingrid Lundberg, Cecilia Wick, Åsa Hallgren, Olle Kämpe
  • Patent number: 10253361
    Abstract: A thermal cycling device for thermally cycling samples of biological material contained in a microcard having a top and bottom surface. The thermal cycling device can include a sample block having an upper surface configured for engaging the bottom surface of a microcard, a vacuum device, and a temperature control system operatively connected with the sample block. The upper surface of the sample block may include a plurality of channels, the channels defining spaces between the sample block and the bottom surface of a microcard that may be positioned thereon. The vacuum device may be in fluid communication with the sample block for drawing gas out of the spaces defined by the channels in the sample block. The vacuum device may be configured for substantially maintaining a vacuum between the sample block and microcard so that a retention force is imparted on the microcard to urge the microcard toward the sample block.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: April 9, 2019
    Assignee: APPLIED BIOSYSTEMS, LLC
    Inventor: Adrian Fawcett
  • Patent number: 10253314
    Abstract: A Ligand-guided-Selection (LIGS) method for identifying highly specific aptamers against a predetermined antigen of a target is provided. LIGS uses a stronger and highly specific bivalent binder (e.g. an antibody) interacting with its cognate antigen to displace specific aptamers from a partially enriched SELEX pool. Elution of the displaced aptamers provides aptamers that are specific to the predetermined antigen.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: April 9, 2019
    Assignee: Research Foundation of the City University of New York
    Inventor: Prabodhika Mallikaratchy
  • Patent number: 10246479
    Abstract: This disclosure provides systems and methods for sequencing nucleic acids using nucleotide analogues and translocation of tags from incorporated nucleotide analogues through a nanopore. In aspects, this disclosure is related to composition, method, and system for sequencing a nucleic acid using tag molecules and detection of translocation through a nanopore of tags released from incorporation of the molecule.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: April 2, 2019
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF COMMERCE
    Inventors: Jingyue Ju, Shiv Kumar, Chuanjuan Tao, Minchen Chien, James J. Russo, John J. Kasianowicz, Joseph W. F. Robertson
  • Patent number: 10246744
    Abstract: Provided are compositions, methods and systems for determining the sequence of a template nucleic acid using a polymerase-based, sequencing-by-binding procedure. An examination step involves monitoring the interaction between a polymerase and template nucleic acid in the presence of one or more nucleotides. Identity of the next correct nucleotide in the sequence is determined without incorporation of any nucleotide into the structure of the primer by formation of a phosphodiester bond. An optional incorporation step can be used after the examination step to extend the primer by one or more nucleotides, thereby incrementing the template nucleotides that can be examined in a subsequent examination step. The sequencing-by-binding procedure does not require the use of labeled nucleotides or polymerases, but optionally can employ these reagents.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: April 2, 2019
    Assignee: OMNIOME, INC.
    Inventors: Kandaswamy Vijayan, Corey M. Dambacher, Eugene Tu, Mark A. Bernard, Joseph Rokicki, Kerry Wilson
  • Patent number: 10240203
    Abstract: The present invention relates to an in vitro method for diagnosing an acute or relapsing phase of inflammatory bowel disease as well as a method for treating the acute or relapsing phase of inflammatory bowel disease. In addition, the present invention relates to a medicament for use in the treatment of inflammatory bowel disease. Further comprised by the present invention is the use of a nucleic acid molecule of SEQ ID NO: 1 or 2 for monitoring the progression of said disease and in vitro diagnosis of an acute or relapsing phase of said disease. Also a device for the diagnosis of said disease and kits for performing the method of the present invention are envisaged by the present invention.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: March 26, 2019
    Assignee: Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Alexander Schmidt, Christoph Cichon
  • Patent number: 10240206
    Abstract: Biomarkers, methods, assays, and kits are provided for predicting the efficacy of adjuvant chemotherapy (ACT) in a subject with early-stage non-small cell lung cancer (NSCLC).
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: March 26, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: W. Douglas Cress, Dung-Tsa Chen
  • Patent number: 10234457
    Abstract: Described herein is an enzyme detection device for use in the detection of enzyme activity in a test sample. Also provided are indicator molecules for use in the detection of enzyme activity, particularly enzyme cleavage activity, in a test sample, and to methods for detecting the presence of enzyme activity.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: March 19, 2019
    Assignee: Mologic Limited
    Inventors: Paul Davis, Gita Parekh
  • Patent number: 10233507
    Abstract: The present disclosure provides a transgenic corn comprising event MON87403 that exhibits increased grain yield. The disclosure also provides cells, plant parts, seeds, plants, commodity products related to the event, and DNA molecules that are unique to the event and were created by the insertion of transgenic DNA into the genome of a corn plant. The disclosure further provides methods for detecting the presence of said corn event nucleotide sequences in a sample, probes and primers for use in detecting nucleotide sequences that are diagnostic for the presence of said corn event.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: March 19, 2019
    Assignee: Monsanto Technology LLC
    Inventors: Thomas R. Adams, John A. Korte, Anagha M. Sant, J. Philip Taylor
  • Patent number: 10233499
    Abstract: The present invention provides novel mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that can be used for a more accurate diagnosis of cystic fibrosis (CF) and CF related disorders. Methods for testing a sample obtained from a subject to determine the presence of one or more mutations in the CFTR gene are provided wherein the presence of one or more mutations indicates that the subject has CF or a CF related disorder, or is a carrier of a CFTR mutation.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 19, 2019
    Assignee: Laboratory Corporation of America Holdings
    Inventors: Elizabeth Rohlfs, Deborah Alexa Sirko-Osadsa, Lynne Rosenblum, Narasimhan Nagan, Zhaoqing Zhou, Ruth Heim
  • Patent number: 10228803
    Abstract: An electrostatic sensing method is provided. An electrostatic sensing device comprising an electrostatic sensing module comprising a first electrostatic sensing element, and a control unit electrically connected to the electrostatic sensing module is provided. The first electrostatic sensing element is one-dimensional semiconducting linear structure. A direct voltage is applied to the first electrostatic sensing element. A sensed object with electrostatic charge is moved to the electrostatic sensing device in a distance near but not touching the first electrostatic sensing element. A resistance changed value of the first electrostatic sensing element is measured.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: March 12, 2019
    Assignees: Tsinghua University, HON HAI PRECISION INDUSTRY CO., LTD.
    Inventors: Xin-He Wang, Dong-Qi Li, Jiang-Tao Wang, Wen-Yun Wu, Yu-Jun He, Peng Liu, Qing-Yu Zhao, Kai-Li Jiang, Shou-Shan Fan
  • Patent number: 10227650
    Abstract: Provided herein are methods and compositions for the detection of silent carriers of chromosomal deletion alleles in a human subject using haploid cells (e.g., sperm cells or egg cells) derived from the subject. The methods provided herein comprise quantitative nucleic acid amplification reactions and determination of a ratio of a target gene to a reference gene, and indicate that a subject is a silent carrier of a null allele corresponding to the target gene if the ratio is at or below a threshold level. The methods provided herein allow for the detection of silent (2+0) carriers of SMA, where the individual has a deletion of the SMN1 gene on one chromosome 5 homolog and two or more copies of the SMN1 gene on other chromosome 5 homolog.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 12, 2019
    Assignee: Athena Diagnostics, Inc.
    Inventors: David A. Hill, Matthew Evans, Corey D. Braastad
  • Patent number: 10227586
    Abstract: The present invention relates to an artificial ncRNA expression library and a method for preparing the same, and particularly the present invention relates to a library securing the stability of the artificial ncRNA by cloning random fragmented DNA that whole genome DNA of E. coli is randomly fragmented to a middle of RNA scaffold having a double stem-loop and a method for preparing the same.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 12, 2019
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Younghoon Lee, Won Kyong Kim, Geunu Bak, Hongmarn Park, Jee Soo Choi, Shinae Suk, Ji Young Lee, Yeongseong Yoon
  • Patent number: 10228375
    Abstract: Water soluble light harvesting multichromophores that have an ultraviolet absorption maximum are provided. In some embodiments, the multichromophores include a conjugated segment including a fused 6-5-6 tricyclic co-monomer and a UV absorbance-modifying co-monomer. The multichromophores may include an acceptor chromophore covalently linked to the multichromophore in energy-receiving proximity therewith. In some embodiments, a specific binding member is covalently linked to the multichromophore. Also provided are methods of evaluating a sample for the presence of a target analyte and methods of labelling a target molecule using compositions including the light harvesting multichromophores. Kits and systems for practicing the subject methods are also provided.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: March 12, 2019
    Assignee: Becton, Dickinson and Company
    Inventors: Yongchao Liang, Frank P. Uckert, Glenn P. Bartholomew, Barry E. Leonard, Brent S. Gaylord
  • Patent number: 10223502
    Abstract: The present invention provides a novel approach for storing, analyzing, and/or accessing biological data in a cloud computing environment. Sequence data generated by a particular sequencing device may be uploaded to the cloud computing environment during a sequencing run, which reduces the on-site storage needs for the sequence data. Analysis of the data may also be performed in the cloud computing environment, and the instructions for such analysis may be set at the originating sequencing device. The sequence data in the cloud computing environment may be shared according to permissions. Further, the sequence data may be modified or annotated by authorized secondary users.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: March 5, 2019
    Assignee: Illumina, Inc.
    Inventors: Alexander G. Dickinson, Francisco Jose Garcia, Robert C. Kain, Scott D. Kahn, Andrew R. Nelson
  • Patent number: 10221450
    Abstract: The invention relates to new methods of moving helicases past spacers on polynucleotides and controlling the loading of helicases on polynucleotides. The invention also relates to new methods of characterizing target polynucleotides using helicases.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: March 5, 2019
    Assignee: Oxford Nanopore Technologies Ltd.
    Inventors: Andrew John Heron, David Antoni Alves, James Anthony Clarke, Marion Louise Crawford, Daniel Ryan Garalde, Graham Hall, Daniel John Turner, James White
  • Patent number: 10221458
    Abstract: Disclosed in the present invention is a method for screening cancer, comprising the following steps: (1) providing a specimen to be detected; (2) detecting the methylation status of CpG sequence of at least one target gene which is at least one of ADRA1D, AJAP1, HS3ST2, MAGI2, POU4F2, POU4F3, PTGDR, SOX17 and SYT9 in genomic DNA of the specimen; (3) determining whether cancer or precancerous lesions are present in the specimen according to the methylation status of at least one target gene.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: March 5, 2019
    Assignee: NATIONAL DEFENSE MEDICAL CENTER
    Inventor: Hungcheng Lai
  • Patent number: 10221446
    Abstract: This disclosure describes a structured polynucleotide, devices that include the structured polynucleotide, and methods involving the structured polynucleotide and/or devices. Generally, the structured polynucleotide includes five domains. A first domain acts as a toehold for an input DNA logic gate to initiate binding to an SCS biomolecule. A second domain acts as a substrate recognition sequence for an upstream DNA logic gate. A third domain acts as a toehold for a output DNA logic gate to initiate binding of the SCS biomolecule to the gate. A fourth domain acts as an effector sequence to alter the state of the output logic gate. A fifth domain acts as a cage sequence to lock the effector sequence in an inactive state until an input gate binds to the structured polynucleotide.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 5, 2019
    Assignee: STC.UNM
    Inventors: Carl Brown, III, Steven Wayde Graves, Darko Stefanovic, Matthew Richard Lakin
  • Patent number: 10214741
    Abstract: Disclosed are vectors and compositions comprising a pol II promoter and an shRNA wherein the shRNA has a sense RNA strand and an antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence in STAT3, VEGFR, or EPOR. Also disclosed are methods of treating retinopathy of prematurity (ROP), methods of inhibiting expression of STAT3, VEGFR, and EPOR, and methods of regulating signaling events associated with intravitreal neovascularization (IVNV).
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: February 26, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventor: Mary Elizabeth Hartnett
  • Patent number: 10214726
    Abstract: Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 26, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard William Wyatt Childs, Yoshiyuki Takahashi, Sachiko Kajigaya, Nanae Harashima
  • Patent number: 10207264
    Abstract: A functional device (and a functional device manufacturing method) includes a first substrate in which a groove is formed in one surface, a second substrate which is integrally disposed by bonding one surface of the second substrate to the one surface of the first substrate, and forms a flow path together with the groove of the first substrate, at least one modification object of a capture body which captures a target substance supplied into the flow path, an electrode which imparts an electrical or a chemical action to the target substance, and a catalyst, in which the modification object is disposed by being modified on a part of an inner surface of the flow path, a bonding portion between the one surface of the first substrate and the one surface of the second substrate is formed by bonding fluorine to silica.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: February 19, 2019
    Assignee: Japan Science and Technology Agency
    Inventors: Takehiko Kitamori, Kazuma Mawatari